Standout Papers

Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism 2015 2026 2018 2022 1.0k
  1. Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism (2017)
    Gary E. Raskob, Nick van Es et al. New England Journal of Medicine
  2. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial (2015)
    Christian T. Ruff, Robert P. Giugliano et al. The Lancet

Immediate Impact

1 from Science/Nature 67 standout
Sub-graph 1 of 21

Citing Papers

Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation
2025 Standout
Stroke
2024 Standout
6 intermediate papers

Works of Minggao Shi being referenced

The impact of a three-factor prothrombin complex concentrate on the anticoagulatory effects of the factor Xa inhibitor edoxaban
2015
Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: Design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation–Thrombolysis In Myocardial Infarction study 48 (ENGAGE AF–TIMI 48)
2010
and 4 more

Author Peers

Author Last Decade Papers Cites
Minggao Shi 2625 1941 329 44 3.3k
Isabelle Mahé 1442 1278 368 164 2.3k
Harry R. Büller 1095 1580 572 28 2.3k
Alan K. Jacobson 4243 2133 689 36 5.4k
David Baanstra 2445 2277 808 9 3.8k
Cesare Manotti 1791 1502 484 59 2.8k
Alexander G.G. Turpie 2678 2768 865 48 3.6k
Theodore E. Spiro 2290 2416 869 65 3.3k
Charles Frost 2700 1702 285 50 3.3k
Ulf Angerås 2225 1770 931 39 3.9k
Jeffrey Friedman 2680 1999 721 51 3.5k

All Works

Loading papers...

Rankless by CCL
2026